";s:4:"text";s:4344:"Regrowth of fingernails and toenails normally requires 3 to 6 months and 6 to 12 months, respectively. At the 150 mg once-a-week dose, the concentration of fluconazole in stratum corneum on day 7 was 23.4 μg/g and 7 days after the second dose was still 7.1 μg/g.
Voriconazole: (CYP2C9 and CYP3A4 inhibitor): Coadministration of oral voriconazole (400 mg Q12h for 1 day, then 200 mg Q12h for 2.5 days) and oral fluconazole (400 mg on day 1, then 200 mg Q24h for 4 days) to 8 healthy male subjects resulted in an increase in Cmax and AUCAn observational study has suggested an increased risk of spontaneous abortion in women treated with fluconazole during the first trimester.There have been reports of multiple congenital abnormalities (including brachycephalia, ears dysplasia, giant anterior fontanelle, femoral bowing and radio-humeral synostosis) in infants whose mothers were treated for at least three or more months with high doses (400-800 mg daily) of fluconazole for coccidioidomycosis.
to children of 11 days-11 months old.
Consequently, reduction of the dose is needed. Ketoconazole is known to cause adrenal insufficiency, and this could also although rarely seen be applicable to fluconazole.Adrenal insufficiency relating to concomitant treatment with Prednisone is described in section 4.5 Erythromycin: Concomitant use of fluconazole and erythromycin has the potential to increase the risk of cardiotoxicity (prolonged QT interval, Amiodarone: concomitant administration of fluconazole with amiodarone may increase QT prolongation. At a dose of 50 mg once daily, the concentration of fluconazole after 12 days was 73 μg/g and 7 days after cessation of treatment the concentration was still 5.8 μg/g. Patients have rarely developed exfoliative cutaneous reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, during treatment with fluconazole. oesophagitis, candiduria, non-invasive bronchopulmonary infections). Longer periods may be used in patients with severely compromised immune function.Up to 28 days.
The patient should be informed of suggestive symptoms of serious hepatic effect (important asthenia, anorexia, persistent nausea, vomiting and jaundice). A three-hour hemodialysis session decreases plasma levels by approximately 50%.
Coadministration of other medicinal products known to prolong the QT interval and which are metabolised via the cytochrome P450 (CYP) 3A4 are contraindicated (see sections 4.3 and 4.5).
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
The mean half-life (hours) was 74 (range 44-185) on day 1 which decreased with time to a mean of 53 (range 30-131) on day 7 and 47 (range 27-68) on day 13.